BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36507841)

  • 1. Combining γ-GT, PIVKA-II, and AFP to predict long-term prognosis in patients with hepatocellular carcinoma after hepatectomy.
    Sun L; Gu M; Cai J; Yang W; Pan B; Wang B; Zhang C; Guo W
    Clin Exp Pharmacol Physiol; 2023 Apr; 50(4):287-297. PubMed ID: 36507841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic value of the γ-glutamyltransferase and alanine transaminase ratio, alpha-fetoprotein, and protein induced by vitamin K absence or antagonist II in hepatitis B virus-related hepatocellular carcinoma.
    Wang G; Lu X; Du Q; Zhang G; Wang D; Wang Q; Guo X
    Sci Rep; 2020 Aug; 10(1):13519. PubMed ID: 32782270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of gamma-glutamyltransferase/aspartate aminotransferase ratio, protein induced by vitamin K absence or antagonist II, and alpha-fetoprotein in hepatitis B virus-related hepatocellular carcinoma.
    Wang Q; Chen Q; Zhang X; Lu XL; Du Q; Zhu T; Zhang GY; Wang DS; Fan QM
    World J Gastroenterol; 2019 Sep; 25(36):5515-5529. PubMed ID: 31576097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prothrombin induced by vitamin K Absence-II versus alpha-fetoprotein in detection of both resectable hepatocellular carcinoma and early recurrence after curative liver resection: A retrospective cohort study.
    Wang MD; Sun LY; Qian GJ; Li C; Gu LH; Yao LQ; Diao YK; Pawlik TM; Lau WY; Huang DS; Shen F; Yang T
    Int J Surg; 2022 Sep; 105():106843. PubMed ID: 35995351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival.
    Nanashima A; Taura N; Abo T; Ichikawa T; Sakamoto I; Nagayasu T; Nakao K
    Dig Dis Sci; 2011 Oct; 56(10):3086-100. PubMed ID: 21706206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of protein induced by absence of vitamin K absence or antagonist II, alpha-fetoprotein and gamma-glutamyltransferase/aspartate aminotransferase ratio for the diagnosis of hepatocellular carcinoma in transplantation candidates.
    Ekmen N; Akalin Ç; Akyildiz M
    Eur J Gastroenterol Hepatol; 2021 Feb; 32(2):294-299. PubMed ID: 32796360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty liver disease: A multicenter analysis.
    Guan MC; Ouyang W; Liu SY; Sun LY; Chen WY; Tong XM; Zhu H; Yang T
    Hepatobiliary Pancreat Dis Int; 2022 Dec; 21(6):559-568. PubMed ID: 35643910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal surveillance of three biomarkers to predict recurrence of hepatocellular carcinoma after radical resection.
    Tong JS; Lu CD; Lu CJ; Zheng S; Mao SQ
    Eur J Gastroenterol Hepatol; 2023 Oct; 35(10):1178-1185. PubMed ID: 37577836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
    Feng H; Li B; Li Z; Wei Q; Ren L
    BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein.
    Suehiro T; Sugimachi K; Matsumata T; Itasaka H; Taketomi A; Maeda T
    Cancer; 1994 May; 73(10):2464-71. PubMed ID: 7513601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of PIVKA-II and AFP secretion status on early recurrence of hepatocellular carcinoma after open and laparoscopic surgery.
    Cai Y; Xie K; Adeeb Alhmoud MN; Lan T; Wan H; Hu D; Lan L; Liu C; Wu H
    Cancer Med; 2023 Sep; 12(17):17866-17877. PubMed ID: 37596739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of clinical pathologic characteristics between alpha-fetoprotein negative and positive hepatocellular carcinoma patients from Eastern and Southern China.
    Chi X; Jiang L; Yuan Y; Huang X; Yang X; Hochwald S; Liu J; Huang H
    BMC Gastroenterol; 2022 Apr; 22(1):202. PubMed ID: 35461226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection.
    Kim DY; Paik YH; Ahn SH; Youn YJ; Choi JW; Kim JK; Lee KS; Chon CY; Han KH
    Oncology; 2007; 72 Suppl 1():52-7. PubMed ID: 18087182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival outcomes of hepatectomy for stage B Hepatocellular carcinoma in the BCLC classification.
    Kamiyama T; Orimo T; Wakayama K; Shimada S; Nagatsu A; Yokoo H; Kamachi H; Yamashita K; Shimamura T; Taketomi A
    World J Surg Oncol; 2017 Aug; 15(1):156. PubMed ID: 28830473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma.
    Miyaaki H; Nakashima O; Kurogi M; Eguchi K; Kojiro M
    J Gastroenterol; 2007 Dec; 42(12):962-8. PubMed ID: 18085353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
    Choi JY; Jung SW; Kim HY; Kim M; Kim Y; Kim DG; Oh EJ
    World J Gastroenterol; 2013 Jan; 19(3):339-46. PubMed ID: 23372355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A nomogram to predict microvascular invasion in early hepatocellular carcinoma.
    Li H; Li T; Hu J; Liu J
    J Cancer Res Ther; 2021 Jul; 17(3):652-657. PubMed ID: 34269295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma.
    Nakagawa T; Seki T; Shiro T; Wakabayashi M; Imamura M; Itoh T; Tamai T; Nishimura A; Yamashiki N; Matsuzaki K; Sakaida N; Inoue K; Okamura A
    Int J Oncol; 1999 Feb; 14(2):281-6. PubMed ID: 9917503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
    Caviglia GP; Abate ML; Gaia S; Petrini E; Bosco C; Olivero A; Rosso C; Ciancio A; Pellicano R; Saracco GM; Rizzetto M; Smedile A
    Panminerva Med; 2017 Dec; 59(4):283-289. PubMed ID: 28650134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region.
    Kim DY; Toan BN; Tan CK; Hasan I; Setiawan L; Yu ML; Izumi N; Huyen NN; Chow PK; Mohamed R; Chan SL; Tanwandee T; Lee TY; Hai TTN; Yang T; Lee WC; Chan HLY
    Clin Mol Hepatol; 2023 Apr; 29(2):277-292. PubMed ID: 36710606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.